
Opinion|Videos|July 22, 2024
Key Consideration and Concerns Around IV and Subcutaneous Biologic Use
A medical expert shares critical insights around biologic utilization.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What about IV biologics excited you the most when they came out? What were your main concerns?
- What about subcutaneous biologics excited you the most when they came out? What were your main concerns?
Advertisement
Related to this article

ProAct Chief Operating Offier Deborah Dempsey says plan sponsors still lack the data and visibility to know whether they were shorted on a 340B claim.

AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.

OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point drop in body mass index and improved mental health.

Yellow eyelid Xanthelasma signals hidden high cholesterol and cardiovascular disease risk, tripling heart attack and stroke odds; Negin Yavari, M.D., and her team urge screening.

Maladaptive coping at baseline raised relapse and symptom risk over 12 months in first episode psychosis, King's College London researchers found.

Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.

ProAct's Deborah Dempsey, Pharm.D., MBA, RPh, explains how 340B discounts to healthcare entities are in conflict with rebates that manufacturers pay to health plan sponsors.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Navitus launches GLP-1 drug management programs
2
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
3
Deborah Dempsey, Pharm.D., MBA, RPh, on 340B discounts vs. rebates | PBMI 2026
4
Judi Health, Employers Health team up to launch new PBM solution
5





